



Supplementary Figure S6. Combination of RNA splicing modulator compounds and ATR inhibition sensitizes U2AF1^{S34F} expressing cells. U2AF1^{WT} and U2AF1^{S34F}-expressing K562 cells were treated with increasing doses of E7107 (0 - 4 nM, 3 fold-dilution) or ATRi (0 – 20 μM, 3 fold-dilution) individually or in combination for 48h. Color-coding denotes the level of viability (green [100% viability] to red [0% viability]) relative to DMSO treatment.